http://www.asm.org/modules/mod_image_show_gk4/cache/mSphere Direct herogk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Podcast Hero Banner3gk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Microbe Online Program Plannergk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/AAAS Fellows Bannergk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Read New JMBE Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
21-01-2017mSphere Direct
21-01-2017Podcast banner
21-01-2017AAAS Fellows
21-01-2017Read new JMBE
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Attend ASM Biothreats Meeting
REGISTER
The ASM filed an Amicus Curiae brief in August, which provided information about scientific matters related to the need and safety of Biosafety Level 4 laboratories. The Massachusetts Supreme Court will hear arguments on September 5 in the case involving public opposition to the construction of a federally funded BSL 4 facility, the National Emerging Infectious Diseases Laboratories (NEIDL), at the Boston University Medical Campus. The ASM brief described the tremendous impact on society of infectious diseases and the emergence of new and resistant infectious diseases globally, in the last 30 years, providing information to the Court about the need for high containment laboratories to study pathogens and to develop new vaccines, diagnostics and therapeutics. The brief described the requirements for strict adherence of high containment laboratories to relevant safety and security standards, practices and procedures, required by government policies.
 

TPL_asm2013_SEARCH

2150